Signs point to FDA approval for Biogen’s experimental Alzheimer’s disease treatment, though there are skeptics

Odds are increasing that Biogen’s experimental and somewhat controversial Alzheimer’s disease drug may get approved after Food and Drug Administration officials said there was enough evidence in clinical trials to prove the therapy’s effectiveness.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.